자궁내막암 시장 규모, 점유율, 성장 분석 : 암 유형별, 치료법별, 진단 방법별, 스테이지별, 최종 용도별, 지역별 - 산업 예측(2025-2032년)
Endometrial Cancer Market Size, Share, Growth Analysis, By Cancer Type (Endometrial carcinoma, Uterine sarcoma), By Treatment (Surgery, Chemotherapy), By Diagnosis Method, By Stage, By End Use, By Region - Industry Forecast 2025-2032
상품코드:1630690
리서치사:SkyQuest Technology Consulting Pvt. Ltd.
발행일:2025년 01월
페이지 정보:영문 157 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 자궁내막암 시장 규모는 2023년에 286억 9,000만 달러에 달하며, 예측 기간(2025-2032년)의 CAGR은 4.9%로, 2024년 301억 달러에서 2032년에는 441억 3,000만 달러로 성장할 전망입니다.
세계의 자궁내막암 시장은 발병률 증가, 인식 제고, 의료 인프라 강화에 힘입어 강력한 성장세를 보이고 있습니다. 분자 프로파일링 및 유전자 검사를 포함한 진단 툴의 혁신은 보다 정확하고 맞춤화된 치료 옵션으로 이어지고 있습니다. 표적치료제, 면역치료제, 병용요법의 출현으로 치료 성적이 개선되면서 시장은 더욱 확대되고 있습니다. 유전체 프로파일링과 액체생검과 같은 발전은 조기 발견과 맞춤형 치료 접근법을 촉진하고 있습니다. 그러나 높은 치료 비용, 고급 의료 서비스에 대한 제한된 접근성, 효과적인 조기 발견 방법의 시급한 필요성 등은 자궁내막암이 전 세계에 미치는 영향에 대처하는 데 있으며, 여전히 큰 걸림돌로 작용하고 있습니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요의 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
자궁내막암 시장 규모 : 암 유형별
시장 개요
자궁내막암
선암
암육종
편평 상피암
기타 유형 암
자궁육종
자궁내막암 시장 규모 : 치료법별
시장 개요
수술
화학요법
방사선 치료
호르몬 요법
표적치료
면역치료
자궁내막암 시장 규모 : 진단 방법별
시장 개요
생검
골반 초음파 검사
자궁경 검사
CT 스캔
기타 진단 방법
자궁내막암 시장 규모 : 스테이지별
시장 개요
스테이지 I
스테이지 II
스테이지 III
스테이지 IV
자궁내막암 시장 규모 : 최종 용도별
시장 개요
병원
암센터
외래 수술 센터
자궁내막암 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
회사 개요
제품 포트폴리오 분석
부문별 점유율 분석
매출의 전년대비 비교(2022-2024)
주요 기업 개요
GlaxoSmithKline plc(GSK)(United Kingdom)
Merck & Co., Inc.(United States)
Notable Product : Keytruda(pembrolizumab)
AstraZeneca plc(United Kingdom)
Notable Product : Imfinzi(durvalumab)
Novartis AG(Switzerland)
Pfizer Inc.(United States)
F. Hoffmann-La Roche AG(Switzerland)
Bristol Myers Squibb Company(United States)
Karyopharm Therapeutics Inc.(United States)
Siemens Healthineers AG(Germany)
Takeda Pharmaceutical Company Limited(Japan)
Incyte Corporation(United States)
Context Therapeutics Inc.(United States)
Evergreen Therapeutics, Inc.(United States)
Sysmex Corporation(Japan)
Gilead Sciences, Inc.(United States)
Johnson & Johnson(United States)
AbbVie Inc.(United States)
Sanofi S.A.(France)
결론과 권장사항
KSA
영문 목차
영문목차
Global Endometrial Cancer Market size was valued at USD 28.69 billion in 2023 and is poised to grow from USD 30.1 billion in 2024 to USD 44.13 billion by 2032, growing at a CAGR of 4.9% during the forecast period (2025-2032).
The global endometrial cancer market is experiencing robust growth, fueled by rising incidence rates, heightened awareness, and enhanced healthcare infrastructure. Innovations in diagnostic tools, including molecular profiling and genetic testing, are leading to more precise and personalized treatment options. The market is further expanding due to the emergence of targeted therapies, immunotherapies, and combination treatment modalities that provide improved outcomes. Advancements such as genomic profiling and liquid biopsies facilitate early detection and tailored treatment approaches. Nevertheless, challenges like high treatment costs, limited access to advanced healthcare services, and the pressing need for effective early detection methods continue to pose significant hurdles in addressing the global impact of endometrial cancer.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Endometrial Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Endometrial Cancer Market Segmental Analysis
Global Endometrial Cancer Market is segmented by Cancer Type, Treatment, Diagnosis Method, Stage, End Use and region. Based on Cancer Type, the market is segmented into Endometrial carcinoma and Uterine sarcoma. Based on Treatment, the market is segmented into Surgery, Chemotherapy, Radiation therapy, Hormone therapy, Targeted therapy and Immunotherapy. Based on Diagnosis Method, the market is segmented into Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan and Other Diagnosis Methods. Based on Stage, the market is segmented into Stage I, Stage II, Stage III and Stage IV. Based on End Use, the market is segmented into Hospitals, Cancer centers and Ambulatory surgical centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Endometrial Cancer Market
The global endometrial cancer market is significantly driven by the rising incidence of this prevalent gynecological cancer. Factors such as obesity, hormonal imbalances, and diabetes are contributing to a steady increase in cases, prompting a growing need for effective diagnostic and therapeutic options. This heightened demand for solutions not only accelerates market growth but also emphasizes the importance of advancements in medical technology and enhanced screening methods. These innovations facilitate early detection and treatment of endometrial cancer, ultimately leading to improved patient outcomes and further stimulating investments in healthcare infrastructure to combat this escalating health concern.
Restraints in the Global Endometrial Cancer Market
One significant challenge facing the global endometrial cancer market is the combination of high treatment costs and restricted healthcare accessibility, particularly in developing countries. The financial burden associated with treatment options like surgeries, chemotherapy, and radiation therapy can be overwhelming for many patients, especially those lacking sufficient health insurance or financial resources. Furthermore, in various regions, inadequate healthcare infrastructure, including a shortage of diagnostic services and specialized professionals, complicates the timely and effective treatment of endometrial cancer. To enhance patient outcomes worldwide, it is essential to tackle these obstacles by improving both the affordability and accessibility of quality healthcare.
Market Trends of the Global Endometrial Cancer Market
The Global Endometrial Cancer market is experiencing a notable trend of increased collaborations and partnerships among pharmaceutical companies and research institutions, aimed at expediting drug development and clinical trials. This strategic synergy enhances the focus on innovative diagnostics and the introduction of novel therapeutic options, ultimately translating into improved patient outcomes. Moreover, the rising incidence of endometrial cancer and heightened awareness surrounding women's health are driving the demand for advanced treatment solutions. As stakeholders prioritize research investments and regulatory approvals, this collaborative landscape is likely to foster a dynamic market, positioning it for accelerated growth in the coming years.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Endometrial Cancer Market Size by Cancer Type & CAGR (2025-2032)
Market Overview
Endometrial carcinoma
Adenocarcinoma
Carcinosarcoma
Squamous Cell Carcinoma
Other Types of Cancer
Uterine sarcoma
Global Endometrial Cancer Market Size by Treatment & CAGR (2025-2032)
Market Overview
Surgery
Chemotherapy
Radiation therapy
Hormone therapy
Targeted therapy
Immunotherapy
Global Endometrial Cancer Market Size by Diagnosis Method & CAGR (2025-2032)
Market Overview
Biopsy
Pelvic Ultrasound
Hysteroscopy
CT Scan
Other Diagnosis Methods
Global Endometrial Cancer Market Size by Stage & CAGR (2025-2032)
Market Overview
Stage I
Stage II
Stage III
Stage IV
Global Endometrial Cancer Market Size by End Use & CAGR (2025-2032)
Market Overview
Hospitals
Cancer centers
Ambulatory surgical centers
Global Endometrial Cancer Market Size & CAGR (2025-2032)
North America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
US
Canada
Europe (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
Brazil
Rest of Latin America
Middle East & Africa (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
